Platin desensitizations in thoracic malignancies and risk factors for breakthrough reactions.

Autor:	Buhari GK; Division of Immunology and Allergy, Department of Chest Disease, Ankara Atatürk Sanatoryum Training and Research Hospital, University of Health Sciences, Ankara, Turkey; gozdekoycu@gmail.com., Kalkan İK; Division of Immunology and Allergy, Department of Chest Disease, Ankara Atatürk Sanatoryum Training and Research Hospital, University of Health Sciences, Ankara, Turkey., Ateş H; Division of Immunology and Allergy, Department of Chest Disease, Ankara Atatürk Sanatoryum Training and Research Hospital, University of Health Sciences, Ankara, Turkey., Bahçecioğlu SN; Division of Immunology and Allergy, Department of Chest Disease, Ankara Atatürk Sanatoryum Training and Research Hospital, University of Health Sciences, Ankara, Turkey., Demir Ş; Division of Immunology and Allergy, Department of Chest Disease, Ankara Atatürk Sanatoryum Training and Research Hospital, University of Health Sciences, Ankara, Turkey., Yeşilkaya S; Division of Immunology and Allergy, Department of Chest Disease, Ankara Atatürk Sanatoryum Training and Research Hospital, University of Health Sciences, Ankara, Turkey., Solak GTV; Division of Immunology and Allergy, Department of Chest Disease, Ankara Atatürk Sanatoryum Training and Research Hospital, University of Health Sciences, Ankara, Turkey., Aksu K; Division of Immunology and Allergy, Department of Chest Disease, Ankara Atatürk Sanatoryum Training and Research Hospital, University of Health Sciences, Ankara, Turkey., Erkekol FÖ; Immunology and Allergy Unit, Medicana International, Ankara Hospital, Ankara, Turkey.
Jazyk:	angličtina
Zdroj:	Allergologia et immunopathologia [Allergol Immunopathol (Madr)] 2023 Mar 01; Vol. 51 (2), pp. 130-136. Date of Electronic Publication: 2023 Mar 01 (Print Publication: 2023).
DOI:	10.15586/aei.v51i2.779
Abstrakt:	Although platin desensitization is a safe and effective alternative for patients with hypersensitivity reactions (HSRs), sometimes breakthrough reactions (BTRs) can be encountered. However, data about the risk factors for BTRs are limited. The aim of this study is to define the outcomes of desensitization, the characteristics of BTRs, and to identify the risk factors for BTRs with platins in thoracic malignancies. This is a retrospective report of patients with thoracic malignancies who underwent platin desensitization. Patients' demographics, initial HSR characteristics, skin test results, desensitization outcomes, and BTR characteristics were recorded. Thirty-three lung cancer and 14 malignant pleural mesothelioma (MPM) patients were included in the study. The culprit drug was cisplatin in 29 and was carboplatin in 18 patients. Skin test positivity was 43.5% with cisplatin, 50% with carboplatin, and it was found to be higher if the interval between the initial HSR and skin testing (ST) was ˃20 days (p = 0.027). One hundred and five desensitization courses were performed. Twenty-two patients had 33 BTRs. Skin test positivity was higher in the BTR-positive group (p = 0.025). BTRs (18.2%; n = 6) were more severe than initial HSR. In the case of epinephrine administration during initial HSR, epinephrine administration during the first BTR was found to be more (p = 0.036). The target dose was achieved in 92.4% of desensitization courses. The number of previous platin infusions ≥10 was found to be an independent risk factor for BTR development (p = 0.036 OR:17.641, 95% CI: 1.211-256.971). Identification of risk factors for BTR will guide appropriate management and desensitization approaches for platin HSRs. Competing Interests: The authors declare no potential conflicts of interest with respect to research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu